Company attributes
Venture Capital Firm attributes
Other attributes
Biotechnology Value Fund is a venture capital firm in California that focuses on undervalued investments. Founded 1993 in San Francisco, California, United States, it invests in early stage ventures, post-IPO equity, series B, series C, grants and post-IPO debt. Its portfolio companies include Kymera Therapeutics, Syndax Pharmaceuticals,Pieris Pharmaceuticals, and Revolution Medicines. As of March 2020, Biotechnology Value Fund has made 31 investments. Their most recent investment was on March 12, 2020, when Kymera Therapeutics raised $102M. Biotechnology Value Fund has had 20 exits, the most notable of which include Evotec, Blueprint Medicines, and IDEAYA Biosciences. Biotechnology Value Fund has raised a single venture fund, Biotechnology Value Fund II.